{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:02:45Z","timestamp":1789401765986,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U25A20632"],"award-info":[{"award-number":["U25A20632"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32571471"],"award-info":[{"award-number":["32571471"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32401053"],"award-info":[{"award-number":["32401053"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M763505"],"award-info":[{"award-number":["2024M763505"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2026AFA033"],"award-info":[{"award-number":["2026AFA033"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2024AFA099"],"award-info":[{"award-number":["2024AFA099"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phrs.2026.108341","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:39:20Z","timestamp":1783957160000},"page":"108341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Engineered novel protease-stable multifunctional peptides attenuate metabolic dysfunction-associated steatotic liver disease via disrupting bile acid micelle and activating PPAR pathway"],"prefix":"10.1016","volume":"231","author":[{"given":"Yawen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishuang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuxiang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4829-012X","authenticated-orcid":false,"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108341_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1623789","article-title":"Global trends and forecasts of nonalcoholic steatohepatitis causing liver cancer incidence and deaths","volume":"15","author":"Cui","year":"2026","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/ije\/6430023","article-title":"Resmetirom: the first disease-specific treatment for MASH","volume":"2025","author":"Mousa","year":"2025","journal-title":"Int. J. Endocrinol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108341_bib3","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/cpt.70103","article-title":"Quantitative approaches to accelerate MASH drug discovery and development","volume":"118","author":"Abouelhassan","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2026.108341_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/hbsn-2024-716","article-title":"Resmetirom as an important cornerstone of multidisciplinary management of metabolic dysfunction-associated steatohepatitis","volume":"14","author":"Au","year":"2025","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"9","key":"10.1016\/j.phrs.2026.108341_bib5","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3390\/biomedicines13092079","article-title":"Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier","volume":"13","author":"Tiwari","year":"2025","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.phrs.2026.108341_bib6","article-title":"Translating Trial to Treatment: A Scoping Review of Resmetirom First Year in Real-World Use for Moderate to Advanced Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis","volume":"17","author":"Vats","year":"2025","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.phrs.2026.108341_bib7","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/biomedicines14040909","article-title":"Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities","volume":"14","author":"Prikhodko","year":"2026","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/pharmaceutics18010086","article-title":"The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis","volume":"18","author":"Tornea","year":"2026","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2026.108341_bib9","doi-asserted-by":"crossref","DOI":"10.2147\/DDDT.S560039","article-title":"Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential","author":"Alamgir","year":"2026","journal-title":"Drug. Des. Devel. Ther."},{"key":"10.1016\/j.phrs.2026.108341_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1510322","article-title":"Targeting fibroblast growth factor (FGF)-21: a promising strategy for metabolic dysfunction-associated steatotic liver disease treatment","volume":"16","author":"Cui","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108341_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2025.143956","article-title":"Plant-derived bioactive peptides and protein hydrolysates for managing MAFLD: A systematic review of in vivo effects","volume":"481","author":"Santos-S\u00e1nchez","year":"2025","journal-title":"Food Chem."},{"issue":"13","key":"10.1016\/j.phrs.2026.108341_bib12","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.3390\/nu17132211","article-title":"Food nutrients and bioactive compounds for managing metabolic dysfunction-associated steatotic liver disease: a comprehensive review","volume":"17","author":"Dungubat","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.phrs.2026.108341_bib13","series-title":"Phytochemicals in Soybeans","first-page":"455","article-title":"Soybean-derived bioactive peptides and their health benefits","author":"Abedin","year":"2022"},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101777","article-title":"From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Zhou","year":"2025","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.phrs.2026.108341_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115603","article-title":"Advanced microbiome therapeutics for oral delivery of peptides and proteins: Advances, challenges, and opportunities","volume":"222","author":"Gelli","year":"2025","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"10","key":"10.1016\/j.phrs.2026.108341_bib16","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3390\/biomedicines12102328","article-title":"Comparative analysis of resmetirom vs. FGF21 analogs vs. GLP-1 agonists in MASLD and MASH: network meta-analysis of clinical trials","volume":"12","author":"Ayesh","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2026.108341_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodhyd.2024.110865","article-title":"Layer-by-layer nanoencapsulation strategies for enhanced oral delivery and function of Lactobacillus plantarum B2","volume":"160","author":"Zhu","year":"2025","journal-title":"Food Hydrocoll."},{"key":"10.1016\/j.phrs.2026.108341_bib18","article-title":"The benefits and applications of Lactobacillus plantarum in food and health: a narrative review","volume":"2201","author":"Zare","year":"2024","journal-title":"Iran. J. Public. Health 53(10"},{"key":"10.1016\/j.phrs.2026.108341_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.crfs.2025.101138","article-title":"Probiotics as a therapeutic strategy for metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis","volume":"11","author":"Lu","year":"2025","journal-title":"Curr. Res. Food Sci."},{"issue":"18","key":"10.1016\/j.phrs.2026.108341_bib20","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.3390\/foods13182992","article-title":"Probiotics and non-alcoholic fatty liver disease: unveiling the mechanisms of Lactobacillus plantarum and Bifidobacterium bifidum in modulating lipid metabolism, inflammation, and intestinal barrier integrity","volume":"13","author":"Lu","year":"2024","journal-title":"Foods"},{"key":"10.1016\/j.phrs.2026.108341_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.1071284","article-title":"Lactobacillus plantarum ZJUIDS14 alleviates non-alcoholic fatty liver disease in mice in association with modulation in the gut microbiota","volume":"9","author":"Cao","year":"2023","journal-title":"Front. Nutr."},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/acs.jafc.5b05088","article-title":"Interaction between tea polyphenols and bile acid inhibits micellar cholesterol solubility","volume":"64","author":"Ogawa","year":"2016","journal-title":"J. Agric. Food Chem."},{"issue":"3","key":"10.1016\/j.phrs.2026.108341_bib23","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1161\/HYPERTENSIONAHA.120.15725","article-title":"SARS-CoV-2 receptor ACE2 (Angiotensin-Converting Enzyme 2) is upregulated in colonic organoids from hypertensive rats","volume":"76","author":"Li","year":"2020","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.phrs.2026.108341_bib24","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1271\/bbb.100338","article-title":"Soystatin (VAWWMY), a novel bile acid-binding peptide, decreased micellar solubility and inhibited cholesterol absorption in rats","volume":"74","author":"Nagaoka","year":"2010","journal-title":"Biosci. Biotechnol. Biochem."},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib25","first-page":"1","article-title":"Impact of \u03b2-cyclodextrin and resistant starch on bile acid metabolism and fecal steroid excretion in regard to their hypolipidemic action in hamsters, Biochim. Biophys. Acta-Mol. Cell Biol. Lipids","volume":"1437","author":"Trautwein","year":"1999"},{"key":"10.1016\/j.phrs.2026.108341_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17576180.2026.2621015","article-title":"Rapid quantification of bile acids in serum by LC-MS\/MS and application to serum bile acid profile in voriconazole administered patients with invasive fungal infections","author":"Yang","year":"2026","journal-title":"Bioanalysis"},{"key":"10.1016\/j.phrs.2026.108341_bib27","series-title":"Bile acids in gastroenterology","author":"Tazuma","year":"2017"},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib28","doi-asserted-by":"crossref","first-page":"G164","DOI":"10.1152\/ajpgi.00392.2010","article-title":"Use of NBD-cholesterol to identify a minor but NPC1L1-independent cholesterol absorption pathway in mouse intestine","volume":"300","author":"Adams","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib30","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1038\/s41467-026-68556-4","article-title":"Investigation of bile salt hydrolase activity in human gut bacteria reveals production of conjugated secondary bile acids","volume":"17","author":"Lucas","year":"2026","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.phrs.2026.108341_bib31","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10533-024-01121-7","article-title":"Microbial hydrogenation of cholesterol to coprostanol by anaerobic bacteria: evidence from Antarctic lacustrine sediment","volume":"167","author":"Chen","year":"2024","journal-title":"Biogeochemistry"},{"issue":"12","key":"10.1016\/j.phrs.2026.108341_bib32","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3390\/foods13121853","article-title":"Effect of bioactive peptides on gut microbiota and their relations to human health","volume":"13","author":"Wijesekara","year":"2024","journal-title":"Foods"},{"key":"10.1016\/j.phrs.2026.108341_bib33","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.crfs.2022.10.031","article-title":"Advances in the stability challenges of bioactive peptides and improvement strategies","volume":"5","author":"Pei","year":"2022","journal-title":"Curr. Res. Food Sci."},{"issue":"5","key":"10.1016\/j.phrs.2026.108341_bib34","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41551-020-0556-3","article-title":"De novo development of proteolytically resistant therapeutic peptides for oral administration","volume":"4","author":"Kong","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"3","key":"10.1016\/j.phrs.2026.108341_bib35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.smj.0000208120.73327.db","article-title":"Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review","volume":"99","author":"Insull","year":"2006","journal-title":"South. Med. J."},{"issue":"4","key":"10.1016\/j.phrs.2026.108341_bib36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.14740\/gr1053w","article-title":"The role of the gut barrier function in health and disease","volume":"11","author":"Assimakopoulos","year":"2018","journal-title":"Gastroenterol. Res."},{"issue":"10","key":"10.1016\/j.phrs.2026.108341_bib37","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.it.2019.08.007","article-title":"Emerging frontiers in microbiome engineering","volume":"40","author":"Inda","year":"2019","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.32592","article-title":"Gut-specific inhibition of PPAR\u03b1 as a novel approach of NAFLD treatment","volume":"77","author":"Zhang","year":"2023","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.phrs.2026.108341_bib39","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/CIRCRESAHA.124.323578","article-title":"Pathways and molecular mechanisms governing LDL receptor regulation","volume":"136","author":"Schmidt","year":"2025","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.phrs.2026.108341_bib40","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/S0022-2275(20)42109-1","article-title":"Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients","volume":"31","author":"Reihner","year":"1990","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.phrs.2026.108341_bib41","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1021\/acs.molpharmaceut.2c00007","article-title":"Bile acid sequestrants for hypercholesterolemia treatment using sustainable biopolymers: Recent advances and future perspectives","volume":"19","author":"Islam","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2026.108341_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155912","article-title":"Deciphering the molecular pathways of saroglitazar: A dual PPAR \u03b1\/\u03b3 agonist for managing metabolic NAFLD","volume":"155","author":"Ezhilarasan","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2026.108341_bib43","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.plipres.2014.02.002","article-title":"Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes","volume":"54","author":"Sahini","year":"2014","journal-title":"Prog. Lipid Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108341_bib44","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","article-title":"Metabolic reprogramming in liver fibrosis","volume":"36","author":"Horn","year":"2024","journal-title":"Cell. Metab."},{"issue":"8","key":"10.1016\/j.phrs.2026.108341_bib45","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/CIRCRESAHA.110.226860","article-title":"The PPAR-RXR transcriptional complex in the vasculature: energy in the balance","volume":"108","author":"Plutzky","year":"2011","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s43014-022-00123-y","article-title":"Research progress in lipid metabolic regulation of bioactive peptides","volume":"5","author":"Ma","year":"2023","journal-title":"Food Prod. Process. Nutr."},{"key":"10.1016\/j.phrs.2026.108341_bib47","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00121.2020","article-title":"Mitochondrial oxidative injury: a key player in nonalcoholic fatty liver disease","author":"Dornas","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108341_bib48","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.7150\/thno.106597","article-title":"Metabolism of hepatic stellate cells in chronic liver diseases: emerging molecular and therapeutic interventions","volume":"15","author":"Yan","year":"2025","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.phrs.2026.108341_bib49","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","article-title":"Mitochondrial dysfunction and signaling in chronic liver diseases","volume":"155","author":"Mansouri","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2026.108341_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119022","article-title":"Mitochondria-targeted antioxidant AntiOxBEN2 prevents metabolic dysfunction-associated steatotic liver disease (MASLD) by enhancing fatty acid oxidation and mitochondrial bioenergetics","author":"Amorim","year":"2026","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.phrs.2026.108341_bib51","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR\u03b1 in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2026.108341_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1447878","article-title":"Regulation of bile acids and their receptor FXR in metabolic diseases","volume":"11","author":"Li","year":"2024","journal-title":"Front. Nutr."},{"key":"10.1016\/j.phrs.2026.108341_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101113","article-title":"FGF15\/19 is required for adipose tissue plasticity in response to thermogenic adaptations","volume":"43","author":"Mor\u00f3n-Ros","year":"2021","journal-title":"Mol. Metab."},{"issue":"51","key":"10.1016\/j.phrs.2026.108341_bib54","doi-asserted-by":"crossref","first-page":"48586","DOI":"10.1021\/acsomega.3c07337","article-title":"NPC1L1 plays a novel role in nonalcoholic fatty liver disease","volume":"8","author":"Xu","year":"2023","journal-title":"Acs Omega"},{"issue":"4","key":"10.1016\/j.phrs.2026.108341_bib55","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/apt.17121","article-title":"Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients' perspectives","volume":"56","author":"Ng","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib56","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell. Metab."},{"issue":"20","key":"10.1016\/j.phrs.2026.108341_bib58","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1073\/pnas.1323599111","article-title":"Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut","volume":"111","author":"Joyce","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2026.108341_bib59","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2021.1875796","article-title":"Blautia-a new functional genus with potential probiotic properties?","volume":"13","author":"Liu","year":"2021","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","article-title":"Bile acid receptors as targets for drug development","volume":"11","author":"Schaap","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2026.108341_bib62","series-title":"Seminars in liver disease","first-page":"330","article-title":"Bile acid-mediated control of liver triglycerides","author":"Fuchs","year":"2013"},{"issue":"10","key":"10.1016\/j.phrs.2026.108341_bib63","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.molmed.2011.05.010","article-title":"Bile acids and colon cancer: Solving the puzzle with nuclear receptors","volume":"17","author":"Degirolamo","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.phrs.2026.108341_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.908011","article-title":"The role of gut microbiota-bile acids axis in the progression of non-alcoholic fatty liver disease","volume":"13","author":"Ni","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.phrs.2026.108341_bib65","series-title":"Seminars in immunopathology","first-page":"2","article-title":"Gut microbiota-derived metabolites tune host homeostasis fate","author":"Kim","year":"2024"},{"issue":"13","key":"10.1016\/j.phrs.2026.108341_bib66","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1007\/s00253-016-7557-x","article-title":"Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option","volume":"100","author":"Wang","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"6086","key":"10.1016\/j.phrs.2026.108341_bib67","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.1223813","article-title":"Host-gut microbiota metabolic interactions","volume":"336","author":"Nicholson","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108341_bib68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.copbio.2014.10.006","article-title":"Novel opportunities for next-generation probiotics targeting metabolic syndrome","volume":"32","author":"Cani","year":"2015","journal-title":"Curr. Opin. Biotechnol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108341_bib69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4236\/wjv.2017.74004","article-title":"New progress regarding the use of lactic acid bacteria as live delivery vectors, treatment of diseases and induction of immune responses in different host species focusing on Lactobacillus species","volume":"7","author":"Shonyela","year":"2017","journal-title":"WJV"},{"issue":"3","key":"10.1016\/j.phrs.2026.108341_bib70","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","article-title":"Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism","volume":"7","author":"Morrison","year":"2016","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib71","doi-asserted-by":"crossref","first-page":"106","DOI":"10.31146\/1682-8658-ecg-161-1-106-116","article-title":"Role of short chain fatty acids in evaluation of gut microbiocenosis disorders and their correction in patients with NAFLD of different stages","author":"Ardatskaya","year":"2019","journal-title":"Exp. Clin. Gastroenterol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108341_bib72","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3350\/cmh.2025.0083","article-title":"Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment","volume":"31","author":"Kim","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.phrs.2026.108341_bib73","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/bs.pmbts.2026.01.029","article-title":"Live biotherapeutics in the clinic: Regulatory pathways, market dynamics, and future trends","volume":"220","author":"Das","year":"2026","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2026.108341_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/biot.70253","article-title":"Enabling Clinical Translation of Oral Probiotics Through Formulation Engineering and Scalable Manufacturing","volume":"21","author":"Liu","year":"2026","journal-title":"Biotechnol. J."},{"issue":"7","key":"10.1016\/j.phrs.2026.108341_bib75","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s12325-015-0229-x","article-title":"Nutraceuticals for serum lipid and blood pressure control in hypertensive and hypercholesterolemic subjects at low cardiovascular risk","volume":"32","author":"Mazza","year":"2015","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2026.108341_bib76","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.copbio.2020.02.016","article-title":"Engineering probiotics for therapeutic applications: recent examples and translational outlook","volume":"65","author":"Aggarwal","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.phrs.2026.108341_bib77","series-title":"Genetically engineered hamster models of Dyslipidemia and atherosclerosis, Atherosclerosis: Methods and Protocols","first-page":"433","author":"Xian","year":"2022"},{"issue":"1","key":"10.1016\/j.phrs.2026.108341_bib78","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/351982","article-title":"Rodent models for metabolic syndrome research","volume":"2011","author":"Panchal","year":"2011","journal-title":"BioMed. Res. Int."},{"issue":"12","key":"10.1016\/j.phrs.2026.108341_bib79","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.molmed.2024.05.013","article-title":"Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Cherubini","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108341_bib80","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1210\/me.2011-1157","article-title":"Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob\/ob mice","volume":"26","author":"Zhang","year":"2012","journal-title":"Mol. Endocrinol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:05:34Z","timestamp":1789398334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":80,"alternative-id":["S1043661826002562"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108341","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered novel protease-stable multifunctional peptides attenuate metabolic dysfunction-associated steatotic liver disease via disrupting bile acid micelle and activating PPAR pathway","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108341"}}